Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.

Maria-Concetta FargnoliM EspositoP DapavoA ParodiM RossiR TiberioS DastoliA M OffidaniG ArgenzianoPaolo GisondiA Lo SchiavoF LoconsoleP PellaF BardazziF CusanoM GattoniM NaccaS P CannavòC PellegriniAntonio Costanzonull null

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)

Brodalumab is effective and safe in the treatment of moderate-to-severe psoriasis in a real-world setting, including in patients with failure to anti-IL17 therapies.

Keyphrases

early onset
high intensity
coronary artery disease
randomized controlled trial
clinical trial
combination therapy